Sue C. Bodine
Showed that turning on the Akt-mTOR pathway is enough, by itself, to make skeletal muscle grow and to stop it from wasting away
Professor, OMRF (since 2023) · President, American Physiological Society (2026) · Professor, University of Iowa Carver College of Medicine (2017–2023) · Professor, UC Davis (2003–2017) · Lab Director, Regeneron Pharmaceuticals (1996–2003) · PhD, UCLA (V. Reggie Edgerton lab, 1985)
Aging & Metabolism Research Program, Oklahoma Medical Research Foundation (OMRF) (Oklahoma City, Oklahoma, USA) ↗ Lab lineagetrained under V. Reggie Edgerton → ORCID0000-0002-5742-9145 ↗
Portrait: Oklahoma Medical Research Foundation (OMRF)
In back-to-back 2001 Nature Cell Biology papers, Bodine, as first author with David Glass and George Yancopoulos at Regeneron (BOD2001), and a companion Rommel et al. study (ROM2001, on which she was second author) established that activating Akt/mTOR is sufficient by itself to trigger muscle hypertrophy and prevent atrophy in vivo — rapamycin blocked hypertrophy in every model tested.
Bodine trained under V. Reggie Edgerton at UCLA (including Soviet Bion space-biology missions), directed muscle/nerve regeneration research at Regeneron, then built labs at UC Davis and University of Iowa extending the findings into disuse atrophy, sarcopenia, and atrogin-1/MuRF1 E3 ligases.
Since 2023 at OMRF; began a term as American Physiological Society president in 2026.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2001 | A | Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo BOD2001 Activating Akt/mTOR alone triggers skeletal-muscle hypertrophy and blocks disuse atrophy; rapamycin blocks hypertrophy in every model. |
| 2001 | M | Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways ROM2001 IGF-1 drives myotube hypertrophy specifically through PI3K/Akt/mTOR and PI3K/Akt/GSK3. |
Co-authors in the Atlas 2
People with a profile here who share at least one study with Sue C. Bodine.
ShowHide
- George D. Yancopoulos 2 shared studies Industry scientist who co-founded Regeneron and led drug discovery there; in this Atlas he is senior author of an early paper showing that Akt/mTOR signalling controls muscle size.
- Trevor N Stitt 2 shared studies Regeneron scientist who worked in David Glass and George Yancopoulos's muscle program on the 2001 papers showing that the Akt/mTOR pathway drives muscle growth and protects against muscle wasting
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.